The enrollment into the Affordable Care Act has been hindered by website technical problems, public backlash and political tension. [Help From the Hill Could Add to Pharma ETFs’ Gains]

IMS projects oncology drugs will experience the most spending in developed countries, with sales up to $84 billion in 2017, followed by $39 billion in diabetes drugs. Pain medicines, though, lead in emerging markets with $25 billion in spending.

Pharmaceutical ETFs include:

  • SPDR S&P Pharmaceuticals ETF (NYSEArca: XPH): up 55.1% year-to-date
  • PowerShares Dynamic Pharmaceuticals Portfolio (NYSEArca: PJP): up 49.3% year-to-date
  • iShares U.S. Pharmaceuticals ETF (NYSEArca: IHE): up 37.2% year-to-date
  • Market Vectors Pharmaceutical ETF (NYSEArca: PPH): up 32.0% year-to-date
  • RBS Global Big Pharma ETN (NYSEArca: DRGS): up 35.1% year-to-date

For more information on the pharma sector, visit our pharmaceuticals category.

Max Chen contributed to this article.

Subscribe to our free daily newsletters!
Please enter your email address to subscribe to ETF Trends' newsletters featuring latest news and educational events.